Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $34.87 billion. The enterprise value is $33.66 billion.
Important Dates
The next confirmed earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 211.37 million shares outstanding. The number of shares has increased by 22.38% in one year.
| Current Share Class | 211.37M |
| Shares Outstanding | 211.37M |
| Shares Change (YoY) | +22.38% |
| Shares Change (QoQ) | +4.67% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 91.38% |
| Float | 190.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 74.49 |
| Forward PS | 50.53 |
| PB Ratio | 27.71 |
| P/TBV Ratio | 32.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 84.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.68, with a Debt / Equity ratio of 0.59.
| Current Ratio | 6.68 |
| Quick Ratio | 6.13 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.49 |
Financial Efficiency
Return on equity (ROE) is -160.54% and return on invested capital (ROIC) is -34.07%.
| Return on Equity (ROE) | -160.54% |
| Return on Assets (ROA) | -27.03% |
| Return on Invested Capital (ROIC) | -34.07% |
| Return on Capital Employed (ROCE) | -42.79% |
| Revenue Per Employee | $313,222 |
| Profits Per Employee | -$813,801 |
| Employee Count | 1,271 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.98 |
Taxes
In the past 12 months, Insmed has paid $4.44 million in taxes.
| Income Tax | 4.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.48% in the last 52 weeks. The beta is 1.03, so Insmed's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +132.48% |
| 50-Day Moving Average | 148.70 |
| 200-Day Moving Average | 99.97 |
| Relative Strength Index (RSI) | 63.99 |
| Average Volume (20 Days) | 1,800,447 |
Short Selling Information
The latest short interest is 9.48 million, so 4.49% of the outstanding shares have been sold short.
| Short Interest | 9.48M |
| Short Previous Month | 10.73M |
| Short % of Shares Out | 4.49% |
| Short % of Float | 4.98% |
| Short Ratio (days to cover) | 4.48 |
Income Statement
In the last 12 months, Insmed had revenue of $398.11 million and -$1.03 billion in losses. Loss per share was -$5.72.
| Revenue | 398.11M |
| Gross Profit | 301.43M |
| Operating Income | -927.68M |
| Pretax Income | -1.03B |
| Net Income | -1.03B |
| EBITDA | -917.46M |
| EBIT | -927.68M |
| Loss Per Share | -$5.72 |
Full Income StatementBalance Sheet
The company has $1.86 billion in cash and $739.04 million in debt, giving a net cash position of $1.12 billion or $5.29 per share.
| Cash & Cash Equivalents | 1.86B |
| Total Debt | 739.04M |
| Net Cash | 1.12B |
| Net Cash Per Share | $5.29 |
| Equity (Book Value) | 1.25B |
| Book Value Per Share | 5.92 |
| Working Capital | 1.77B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$844.55 million and capital expenditures -$24.02 million, giving a free cash flow of -$868.57 million.
| Operating Cash Flow | -844.55M |
| Capital Expenditures | -24.02M |
| Free Cash Flow | -868.57M |
| FCF Per Share | -$4.11 |
Full Cash Flow StatementMargins
Gross margin is 75.72%, with operating and profit margins of -233.02% and -259.82%.
| Gross Margin | 75.72% |
| Operating Margin | -233.02% |
| Pretax Margin | -258.70% |
| Profit Margin | -259.82% |
| EBITDA Margin | -230.46% |
| EBIT Margin | -233.02% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.38% |
| Shareholder Yield | -22.38% |
| Earnings Yield | -2.97% |
| FCF Yield | -2.50% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $160.47, which is -2.72% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $160.47 |
| Price Target Difference | -2.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 67.04% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 3.44 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.44 |
| Piotroski F-Score | 3 |
